Brief: Alzamend Neuro Announces Initiation Date Of Phase II Clinical Trial Of AL001 For Treatment Of Bipolar Disorder To Take Place At Massachusetts General Hospital
04/03/2025 14:14
March 4 (Reuters) - Alzamend Neuro Inc ALZN.O: ALZAMEND NEURO ANNOUNCES INITIATION DATE OF PHASE II CLINICAL TRIAL OF AL001 FOR TREATMENT OF BIPOLAR DISORDER TO TAKE PLACE AT MASSACHUSETTS GENERAL HOSPITAL Source text: ID:nGNX4QpP51 Further company coverage: ALZN.O (Reuters.Briefs@thomsonreuters.com)
Recent news on Alzamend Neuro
See all newsAlzamend Neuro Inc reports results for the quarter ended April 30 - Earnings Summary
Alzamend Neuro Inc expected to post a loss of 23 cents a share - Earnings Preview
Alzamend Neuro Inc expected to post a loss of 56 cents a share - Earnings Preview
Alzamend Neuro Inc reports results for the quarter ended April 30 - Earnings Summary
Alzamend Neuro Inc expected to post a loss of 67 cents a share - Earnings Preview